Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer

Spencer, 2015, Intelligent nanoparticles for advanced drug delivery in cancer treatment, Curr Opin Chem Eng, 7, 84, 10.1016/j.coche.2014.12.003 Kunstfeld, 2003, Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model, J Invest Dermatol, 120, 476, 10.1046/j.1523-1747.2003.12057.x Gregoriadis, 1973, Drug entrapment in liposomes, FEBS Lett, 36, 292, 10.1016/0014-5793(73)80394-1 Juliano, 1978, Pharmacokinetics of liposome-encapsulated antitumor drugs and implications for therapy, Ann N Y Acad Sci, 308, 411, 10.1111/j.1749-6632.1978.tb22038.x Nigavekar, 2004, 3H dendrimer nanoparticle organ/tumor distribution, Pharm Res, 21, 476, 10.1023/B:PHAM.0000019302.26097.cc Morgan, 2005, Dendritic supramolecular assemblies for drug delivery, Chem Commun, 14, 4309, 10.1039/b502411k Loo, 2004, Nanoshell-enabled photonics-based imaging and therapy of cancer, Technol Cancer Res Treat, 3, 33, 10.1177/153303460400300104 Smith, 2008, Bioconjugated quantum dots for in vivo molecular and cellular imaging, Adv Drug Deliv Rev, 60, 1226, 10.1016/j.addr.2008.03.015 Bagalkot, 2007, Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer, Nano Lett, 7, 3065, 10.1021/nl071546n Adair, 2010, Nanoparticulate alternatives for drug delivery, ACS Nano, 4, 4967, 10.1021/nn102324e Altinoglu, 2009, Calcium phosphate nanocomposite particles: a safer and more effective alternative to conventional chemotherapy?, Future Oncol, 5, 279, 10.2217/fon.09.4 Tabakovic, 2012, Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 4, 96, 10.1002/wnan.163 Morgan, 2008, Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery, Nano Lett, 8, 4108, 10.1021/nl8019888 Barth, 2013, PhotoImmunoNanoTherapy reveals an anticancer role for sphingosine kinase 2 and dihydrosphingosine-1-phosphate, ACS Nano, 7, 2132, 10.1021/nn304862b Altinoglu, 2008, Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer, ACS Nano, 2, 2075, 10.1021/nn800448r Muddana, 2009, Photophysics of Cy3-encapsulated calcium phosphate nanoparticles, Nano Lett, 9, 1559, 10.1021/nl803658w Barth, 2011, Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia, ACS Nano, 5, 5325, 10.1021/nn2005766 Barth, 2010, Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo, ACS Nano, 4, 1279, 10.1021/nn901297q Clawson, 2017, A cholecystokinin B receptor-specific DNA aptamer for targeting pancreatic ductal adenocarcinoma, Nucleic Acid Ther, 27, 23, 10.1089/nat.2016.0621 Kester, 2008, Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells, Nano Lett, 8, 4116, 10.1021/nl802098g Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 Neesse, 2011, Stromal biology and therapy in pancreatic cancer, Gut, 60, 861, 10.1136/gut.2010.226092 Duschinsky, 1957, The synthesis of 5-Fluoropyrimidines, J Am Chem Soc, 79, 4559, 10.1021/ja01573a087 Longley, 2003, 5-Fluorouracil: mechanisms of action and clinical strategies, Nat Rev Cancer, 3, 330, 10.1038/nrc1074 de Sousa, 2014, Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer, Eur J Pharmacol, 741, 8, 10.1016/j.ejphar.2014.07.041 Ewald, 2008, Nucleoside analogs: molecular mechanisms signaling cell death, Oncogene, 27, 6522, 10.1038/onc.2008.316 Diasio, 1989, Clinical pharmacology of 5-fluorouracil, Clin pharmacokinet, 16, 215, 10.2165/00003088-198916040-00002 Baker, 2013, Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase, Drug Metab Dispos, 41, 541, 10.1124/dmd.112.048769 Heinemann, 1992, Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation, Cancer Res, 52, 533 Abbruzzese, 1991, A phase I clinical, plasma, and cellular pharmacology study of gemcitabine, J Clin Oncol, 9, 491, 10.1200/JCO.1991.9.3.491 Wang, 2014, Recent studies of 5-fluorouracil resistance in pancreatic cancer, World J Gastroenterol, 20, 15682, 10.3748/wjg.v20.i42.15682 Rathos, 2012, Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers, J Transl Med, 10, 161, 10.1186/1479-5876-10-161 Morgan, 2011, The colloidal stability of fluorescent calcium phosphosilicate nanoparticles: the effects of evaporation and redispersion on particle size distribution, Nanoscale, 3, 2044, 10.1039/c0nr00995d Wang, 2006, Dispersion of SiO2-based nanocomposites with high performance liquid chromatography, J Phys Chem B, 110, 4679, 10.1021/jp0547010 Cabral, 2011, Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size, Nat Nanotechnol, 6, 815, 10.1038/nnano.2011.166 Gmeiner, 2015, The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2, Prostate, 75, 360, 10.1002/pros.22922 Gmeiner, 2015, Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway, Leuk Res, 39, 229, 10.1016/j.leukres.2014.11.006 Gmeiner, 2014, Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors, J Neurooncol, 116, 447, 10.1007/s11060-013-1321-1 Farrell, 2009, Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer, Gastroenterology, 136, 187, 10.1053/j.gastro.2008.09.067 van der Wilt, 2001, Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors, Cancer Res, 61, 3675 Lockshin, 1984, Spectroscopic studies of ternary complexes of thymidylate synthetase, deoxyribonucleotides, and folate analogs, J Biol Chem, 259, 11346, 10.1016/S0021-9258(18)90868-9 Patel, 2012, A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing, Oncotarget, 3, 678, 10.18632/oncotarget.554 Parker, 2009, Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer, Chem Rev, 109, 2880, 10.1021/cr900028p Matuo, 2009, 5-fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line, J Appl Toxicol, 29, 308, 10.1002/jat.1411 Ammendola, 2015, Microvascular density and endothelial area correlate with Ki-67 proliferative index in surgically-treated pancreatic ductal adenocarcinoma patients, Oncol Lett, 10, 967, 10.3892/ol.2015.3286 Tacelosky, 2012, Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer, Discov Med, 13, 275 Pradere, 2014, Synthesis of nucleoside phosphate and phosphonate prodrugs, Chem Rev, 114, 9154, 10.1021/cr5002035 Li, 2014, Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials, PLoS One, 9, e104346, 10.1371/journal.pone.0104346 Wong, 2015, Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread, Cancer Cell, 27, 123, 10.1016/j.ccell.2014.10.015 Skrypek, 2013, The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the concentrative nucleoside transporter family, Oncogene, 32, 1714, 10.1038/onc.2012.179 Ohhashi, 2008, Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer, Anticancer Res, 28, 2205 van Kuilenburg, 2012, Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>a mutation in DPYD by means of a Bayesian limited sampling strategy, Clin Pharmacokinet, 51, 163, 10.1007/BF03257473 Kline, 2013, Personalizing colon cancer therapeutics: targeting old and new mechanisms of action, Pharmaceuticals, 6, 988, 10.3390/ph6080988 Ciccolini, 2010, Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies, J Clin Oncol, 28, 160, 10.1200/JCO.2009.24.4491 ND, 2015, Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo, PloS one, 10, e0115636, 10.1371/journal.pone.0115636 Shore, 2003, Review article: chemotherapy for pancreatic cancer, Aliment Pharmacol Ther, 18, 1049, 10.1111/j.1365-2036.2003.01781.x